Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by European Lung Cancer Working Party
Information provided by (Responsible Party):
European Lung Cancer Working Party Identifier:
First received: March 16, 2009
Last updated: February 11, 2015
Last verified: February 2015
The primary aim of the study is to identify a predictive molecular signature for response to chemotherapy, according to WHO criteria, in patients with non-small cell lung cancer by studying the transcriptome (miRNAs and mRNAs) and the single nucleotide polymorphism (SNPs) by using high throughput techniques.

Condition Intervention
Non Small Cell Lung Carcinoma
Drug: Chemotherapy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer : a Prospective Study

Resource links provided by NLM:

Further study details as provided by European Lung Cancer Working Party:

Primary Outcome Measures:
  • Response rate [ Time Frame: response will be assessed every 3 cycles of chemotherapy according to WHO criteria ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Survival [ Time Frame: Survival will be dated from the date of treatment ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: Period between the date of treatment and the date of first progression or death ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: period between the day of treatment and the date of first progression in patients with an objective response ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: March 2009
Estimated Study Completion Date: March 2021
Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website
Drug: Chemotherapy
Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological diagnosis of non-small-cell lung cancer (NSCLC)
  • Obtention of a biopsy of the tumour according to the procedure defined in the protocol
  • NSCLC of any stage to be treated by standard conventional first-line chemotherapy, as defined in the ELCWP guidelines (
  • Presence of at least one assessable lesion
  • Availability for participating in the detailed follow-up of the protocol
  • Signed informed consent.
  • Age above 18 years

Exclusion Criteria:

  • Patient who was previously treated with chemotherapy for NSCLC or who has any contra-indication precluding the administration of conventional chemotherapy for NSCLC
  • NSCLC treated by exclusive surgery or radiotherapy
  • A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00864266

Contact: Nathalie Leclercq, RN 0032/2/5390496
Contact: Thierry Berghmans, MD 0032/2/5390496

Department of Pneumology Clinique Saint-Luc Recruiting
Bouge, Belgium, 5004
Contact: Oswald Van Cutsem, MD         
Principal Investigator: Oswald Van Cutsem, MD         
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet Recruiting
Brussels, Belgium, 1000
Contact: Thierry Berghmans, MD    0032/2/5390496      
Principal Investigator: Thierry Berghmans, MD         
Service de Pneumologie Hôpital Erasme Recruiting
Brussels, Belgium, 1070
Contact: Paul deVuyst, MD, PhD         
Contact: Dimitri Leducq, MD         
Principal Investigator: Paul deVuyst, MD         
Department of Pneumology Hôpital Saint-Joseph Recruiting
Gilly, Belgium, 6060
Contact: Benoît Colinet, MD         
Principal Investigator: Benoît Colinet, MD         
Hôpital Ambroise Paré Recruiting
Mons, Belgium, 7000
Contact: Stéphane Holbrechts, MD         
Sub-Investigator: Patricia Wackenier, MD         
Principal Investigator: Stéphane Holbrechts, MD         
Department of Pneumology Centre Hospitalier de Mouscron Recruiting
Mouscron, Belgium, 7700
Contact: Christian Tulippe, MD         
Principal Investigator: Christian Tulippe, MD         
Sponsors and Collaborators
European Lung Cancer Working Party
Study Chair: Thierry Berghmans, MD European Lung Cancer Working Party
  More Information

Additional Information:
No publications provided by European Lung Cancer Working Party

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: European Lung Cancer Working Party Identifier: NCT00864266     History of Changes
Other Study ID Numbers: 01082
Study First Received: March 16, 2009
Last Updated: February 11, 2015
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by European Lung Cancer Working Party:
Non small cell lung carcinoma
Response prediction

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on November 25, 2015